Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,165 USD | +3,10% | -7,54% | +38,94% |
Omzet 2024 * | 28,72 mln. 26,86 mln. | Omzet 2025 * | 59,14 mln. 55,31 mln. | Marktkapitalisatie | 196 mln. 183 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -94 mln. -87,91 mln. | Nettowinst (verlies) 2025 * | -107 mln. -100 mln. | EV/omzet 2024 * | 6,81 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,31 x |
K/w-verhouding 2024 * |
-2,58
x | K/w-verhouding 2025 * |
-2,6
x | Werknemers | 93 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,06% |
Recentste transcriptie over X4 Pharmaceuticals, Inc.
1 dag | +3,10% | ||
1 week | -7,54% | ||
Lopende maand | -16,19% | ||
1 maand | -17,38% | ||
3 maanden | +50,36% | ||
6 maanden | +64,52% | ||
Lopend jaar | +38,94% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paula Ragan
FOU | Founder | 54 | 01-01-10 |
Adam Mostafa
DFI | Director of Finance/CFO | 44 | 01-09-18 |
Mary DiBiase
COO | Chief Operating Officer | 63 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Wyzga
CHM | Chairman | 69 | 01-07-18 |
David McGirr
BRD | Director/Board Member | 69 | 01-09-17 |
Paula Ragan
FOU | Founder | 54 | 01-01-10 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.00% | 34 M€ | +2,14% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,165 | +3,10% | 11 166 148 |
25-04-24 | 1,13 | -12,40% | 3 445 833 |
24-04-24 | 1,29 | +4,88% | 2 249 760 |
23-04-24 | 1,23 | -9,56% | 3 530 660 |
22-04-24 | 1,36 | +7,94% | 2 435 880 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+38,94% | 196 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,73 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |